6Muijsers R B, Goa K L. A review of its therapeutic use in mild-tomoderate ulcerative colitis [J]. Drugs, 2002,62 (11): 1689 - 1705.
7Ardizzone S, Porro G B. Comparative tolerability of therapies for ulcerative colitis [J]. Drug Saf, 2002,25 ( 8 ) :561 - 582.
8Hirohata S, Ohshima N, Yanagida T, et al. Regulation of human B cell function by sulfasalazine and its metabolites [J]. Int Immunopharmacol, 2002 ,2 ( 5 ) :631 - 640.
9Kamm M A. Maintenance of remission in ulcerative colitis[J]. Aliment Pharmacol Ther,2002 , 16 ( Suppl 4) :21 - 24.
10Gisbert J P, Gomollon F, Mate J, et al. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review[J]. Dig Dis Sci, 2002 ,47(3) :471 -488.
4Sinha VR, Kumria R. Microbially triggered drug delivery to the colon[J]. Eur J Pharm Sci, 2003, 18(1):3-18.
5Khan MZ, Stedul HP, Kurjakovic N. A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. Ⅱ. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations[J]. Drug Det, Ind Pharm, 2000, 26(5):549-554.
6Sangalli ME, Maroni A, Zema L, et al. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivety[J]. J Control Rdease, 2001, 73( 1): 103 -110
7Muraoka M, Hu Z, Shimokawa T, et al. Evaluation of intestinal pressure-controlled colon deliveny capsule containing caffeine as a model drug in human volunteers[J].J Control, 1998, 52(1/2):119- 129.
8Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation[ J ]. Int J Pharm, 2002, 235(1/2) : 1 - 15.
9Prasad YV, Krishnaiah YS, Satyanarayana S. In vitro evaluation of guar gum as a cartier for colon-specific drug delivery[J]. J Control Release, 1998, 51(2/3):281-287.
10Wiwattanapatapee R,Lomlim L,Saramunee K.Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid[J].J Control Release,2003,88(1):1-9
